RT Journal Article
SR Electronic
T1 Allergen immunotherapy for the treatment of allergic rhinitis and/or asthma: an umbrella review
JF CMAJ Open
FD Canadian Medical Association
SP E373
OP E385
DO 10.9778/cmajo.20160066
VO 5
IS 2
A1 Elliott, Jesse
A1 Kelly, Shannon E.
A1 Johnston, Amy
A1 Skidmore, Becky
A1 Gomes, Tara
A1 Wells, George A.
YR 2017
UL http://www.cmajopen.ca/content/5/2/E373.abstract
AB Background: Allergic rhinitis and asthma are important public health concerns, yet there is no consensus about the benefits and harms of allergen-specific immunotherapy to treat these conditions. We performed an umbrella review of systematic reviews summarizing the current evidence for the benefits and harms of subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT).Methods: We searched MEDLINE, Embase, the Cochrane Library and the grey literature from Jan. 1, 2010 to Nov. 20, 2016 for systematic reviews of randomized controlled trials or prospectively controlled studies involving children or adults with allergic rhinitis or asthma. Outcomes were summarized narratively (benefits: total combined symptom-medication score, symptom score, medication score, disease-specific quality of life, adherence; harms: anaphylaxis, death, local and systemic reactions).Results: Twenty-three systematic reviews were included. SCIT and SLIT were more effective than placebo for most outcomes. SCIT was better than SLIT at improving medication and symptom scores, with no differences in quality of life; however, data were limited for this comparison. Anaphylaxis and death were infrequently reported. Few reviews assessed benefits or harms among children.Interpretation: Allergen immunotherapy appears to be effective among patients with allergic rhinitis and asthma. The safety of allergen immunotherapy is not conclusively established, although death and anaphylaxis appear to be rare. PROSPERO no.: CRD42015024590